These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23906502)

  • 1. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.
    Bounfour T; Bouaziz JD; Bézier M; Cordoliani F; Saussine A; Petit A; Juillard C; Bagot M; Rybojad M
    J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1150-7. PubMed ID: 23906502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
    Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
    Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
    Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
    Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
    Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature.
    Milisenda JC; Doti PI; Prieto-González S; Grau JM
    Semin Arthritis Rheum; 2014 Oct; 44(2):228-33. PubMed ID: 24830790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study.
    Kampylafka EI; Kosmidis ML; Panagiotakos DB; Dalakas M; Moutsopoulos HM; Tzioufas AG
    Clin Exp Rheumatol; 2012; 30(3):397-401. PubMed ID: 22510247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
    Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
    Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
    Chérin P; Herson S
    Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study.
    Théaudin M; Lozeron P; Lacroix C; Chrétien P; Ducot B; Denier C; Adams D
    Rev Neurol (Paris); 2011 Dec; 167(12):897-904. PubMed ID: 22023823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
    Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
    J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study").
    Aggarwal R; Charles-Schoeman C; Schessl J; Dimachkie MM; Beckmann I; Levine T
    Medicine (Baltimore); 2021 Jan; 100(1):e23677. PubMed ID: 33429735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravenous immunoglobulin treatment in autoimmune diseases].
    Danieli MG; Calcabrini L; Marchetti A; Calabrese V; Pettinari L; Massaccesi C; Gabrielli A; Danieli G
    Recenti Prog Med; 2007 Jun; 98(6):322-6. PubMed ID: 17580523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
    Dalakas MC
    Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
    Dalakas MC
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis.
    Galimberti F; Li Y; Fernandez AP
    J Am Acad Dermatol; 2015 Jul; 73(1):174-6. PubMed ID: 26089058
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience.
    Wetter DA; Davis MD; Yiannias JA; Gibson LE; Dahl MV; el-Azhary RA; Bruce AJ; Lookingbill DP; Ahmed I; Schroeter AL; Pittelkow MR
    Mayo Clin Proc; 2005 Jan; 80(1):41-7. PubMed ID: 15667028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
    Raju R; Dalakas MC
    Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.